Article
Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy
2020-08-21
Abstract excerpt
Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel cytokine-driven hyper-inflammation, thrombotic microangiopathy and NET-driven immunothrombosis, thereby leading to multi-organ failure. Complement therapeutics have gained traction as candidate drugs for countering the detrimental consequences of SARS-CoV-2 infection. Whet...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9b7adfcf-543e-519d-917d-fb8ee5f7454b
- DOI
- 10.1101/2020.08.17.20174474
